Profile data is unavailable for this security.
About the company
VYNE Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need. Its lead program is repibresib gel (also known as VYN201), a topically administered, small-molecule pan-BD bromodomain and extra-terminal (BET) inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, an oral, small-molecule BD2-selective BET inhibitor. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
- Revenue in USD (TTM)524.00k
- Net income in USD-33.79m
- Incorporated2011
- Employees13.00
- LocationVyne Therapeutics Inc685 Route 202/206 N., Suite 301BRIDGEWATER 08807United StatesUSA
- Phone+1 (650) 486-1416
- Fax+1 (302) 655-5049
- Websitehttps://vynetherapeutics.com/
More ▼
Mergers & acquisitions
| Acquired company | VYNE:NAQ since announced | Transaction value |
|---|---|---|
| Yarrow Bioscience Inc | 48.35% | 200.00m |
Data delayed at least 15 minutes, as of Feb 17 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lixte Biotechnology Holdings Inc | 0.00 | -4.13m | 17.23m | 2.00 | -- | 7.30 | -- | -- | -1.18 | -1.18 | 0.00 | 0.8612 | 0.00 | -- | -- | 0.00 | -114.55 | -113.03 | -130.06 | -121.30 | -- | -- | -- | -- | -- | -1,017.39 | 0.00 | -- | -- | -- | 29.51 | -- | -- | -- |
| LeonaBio Inc | 0.00 | -37.72m | 17.31m | 26.00 | -- | 0.6464 | -- | -- | -9.68 | -9.68 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -64.88 | -36.31 | -87.99 | -38.92 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 17.62 | -- | -- | -- |
| Serina Therapeutics Inc | 130.00k | -18.59m | 17.60m | 12.00 | -- | -- | -- | 135.35 | -1.88 | -1.88 | 0.0133 | 0.1669 | 0.0131 | -- | -- | 10,833.33 | -187.74 | -188.54 | -- | -- | -- | -- | -14,331.54 | -7,513.03 | -- | -730.13 | 0.6444 | -- | -60.56 | -49.64 | 24.74 | -- | -49.05 | -- |
| Jupiter Neurosciences Inc | 0.00 | -7.60m | 19.27m | 4.00 | -- | 334.35 | -- | -- | -0.2296 | -0.2296 | 0.00 | 0.0017 | 0.00 | -- | -- | 0.00 | -570.85 | -383.24 | -- | -- | -- | -- | -- | -902.90 | -- | -- | 0.7183 | -- | -- | -- | 49.00 | -- | -- | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -7.98m | 19.62m | 2.00 | -- | 2.49 | -- | -- | -0.1942 | -0.1942 | 0.00 | 0.1932 | 0.00 | -- | -- | 0.00 | -63.16 | -108.15 | -69.69 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.45 | -- | -- | -- |
| Vyne Therapeutics Inc | 524.00k | -33.79m | 19.75m | 13.00 | -- | 0.5876 | -- | 37.69 | -0.7917 | -0.7888 | 0.0123 | 1.01 | 0.0093 | -- | -- | 40,307.69 | -60.16 | -107.54 | -70.67 | -136.47 | -- | -- | -6,448.47 | -1,720.83 | -- | -- | 0.00 | -- | 18.16 | -- | -42.82 | -- | 60.46 | -- |
| Provectus Biopharmaceuticals Inc | 350.44k | -6.63m | 19.89m | 6.00 | -- | -- | -- | 56.75 | -0.0158 | -0.0158 | 0.0008 | -0.0146 | 0.5736 | -- | -- | 58,406.67 | -1,102.23 | -267.67 | -- | -- | -- | -- | -1,921.64 | -1,092.28 | -- | -27.00 | -- | -- | 10.66 | -- | -52.58 | -- | -- | -- |
| Oncotelic Therapeutics Inc | 0.00 | -1.67m | 20.31m | 26.00 | -- | 2.23 | -- | -- | -0.0041 | -0.0041 | 0.00 | 0.0206 | 0.00 | -- | -- | 0.00 | -7.00 | -20.78 | -19.04 | -43.80 | -- | -- | -- | -1,590.30 | -- | -0.5591 | 0.632 | -- | -100.00 | -- | 42.76 | -- | -- | -- |
| Regentis Biomaterials Ltd | 0.00 | -5.20m | 20.35m | -- | -- | -- | -- | -- | -1.00 | -1.00 | 0.00 | -1.87 | 0.00 | -- | -- | -- | -1,548.81 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 226.60 | -- | -- | -- |
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 20.47m | 18.00 | -- | 1.44 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| Vistagen Therapeutics Inc | 805.00k | -67.05m | 21.00m | 59.00 | -- | 0.4124 | -- | 26.09 | -1.90 | -1.90 | 0.0228 | 1.29 | 0.0102 | -- | -- | 14,375.00 | -85.21 | -55.19 | -99.91 | -59.56 | -- | -- | -8,328.70 | -5,842.62 | -- | -- | 0.0074 | -- | -54.32 | -- | -75.12 | -- | -- | -- |
| Neuphoria Therapeutics Inc | 15.66m | -9.47m | 21.83m | 7.00 | -- | 0.7651 | -- | 1.39 | -3.77 | -3.77 | 8.42 | 5.31 | 0.6233 | -- | 266.10 | 2,237,532.00 | -37.69 | -35.39 | -44.48 | -39.01 | -- | -- | -60.47 | -375.66 | -- | -- | 0.0026 | -- | -- | 246.65 | 97.61 | -- | -- | -- |
| Polyrizon Ltd | 0.00 | -1.16m | 22.16m | 1.00 | -- | 0.7415 | -- | -- | -582.43 | -582.43 | 0.00 | 18.75 | 0.00 | -- | -- | 0.00 | -11.74 | -80.79 | -12.20 | -179.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.91 | -- | -- | -- |
| NanoViricides, Inc | 0.00 | -8.13m | 22.22m | 7.00 | -- | 2.52 | -- | -- | -0.5115 | -0.5115 | 0.00 | 0.4087 | 0.00 | -- | -- | 0.00 | -80.86 | -43.34 | -94.03 | -45.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.14 | -- | 45.82 | -- |
| Apollomics Inc | 8.50m | -31.19m | 22.32m | 13.00 | -- | -- | -- | 2.63 | -26.61 | -26.61 | 8.01 | -3.99 | 0.3721 | -- | -- | 653,846.10 | -136.51 | -- | -276.35 | -- | -- | -- | -366.92 | -- | -- | -- | -- | -- | -- | -- | 68.80 | -- | -- | -- |
Data as of Feb 17 2026. Currency figures normalised to Vyne Therapeutics Inc's reporting currency: US Dollar USD
12.43%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nantahala Capital Management LLCas of 31 Dec 2025 | 1.00m | 3.00% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 851.35k | 2.56% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 638.49k | 1.92% |
| Shay Capital LLCas of 30 Sep 2025 | 492.58k | 1.48% |
| Ikarian Capital LLCas of 30 Sep 2025 | 290.00k | 0.87% |
| Geode Capital Management LLCas of 31 Dec 2025 | 225.15k | 0.68% |
| Two Sigma Investments LPas of 30 Sep 2025 | 220.79k | 0.66% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 183.44k | 0.55% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 130.10k | 0.39% |
| Boothbay Fund Management LLCas of 30 Sep 2025 | 106.46k | 0.32% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
